Under the partnership, the University of Miami will provide samples and Berg will analyze them using its Interrogative Biology platform.
PrediXcan combines gene expression-level information with trait data to predict which genes likely play a role in heritable diseases and observed phenotypes.
The researchers compared five programs used to call variants from pooled sequence data evaluating them in terms of run times, memory usage, sensitivity, and specificity.
The method detects somatic copy number alterations in whole-exome datasets without requiring input from users and irrespective of sequencing platform.
CiViC provides a communal forum for capturing and sharing written summaries, drawn from published literature, about the clinical relevance of mutations found in cancer.
The firm plans to launch several products based on its proprietary machine learning method for identifying variants that alter cellular biochemistry and cause disease.
The ISCB is currently mulling offering an industry track at ISMB, providing training workshops and internships for students, and more.
The method uses a probabilistic approach to mine drug structure, side effects, and genomic and clinical data to identify new drug targets and mechanisms of action.
SQream's first product for the space is based on its database technology and provides tools for storing and analyzing genomic sequence data.
Eisai will use Genomics' tools in its drug R&D efforts including for target selection, validation, and more.
The Washington Post reports that a Russian Academy of Sciences commission has led to the retraction of hundreds of scientific papers.
The Los Angeles Times' Daily Pilot reports the chief executive of Vantari Genetics has pleaded guilty in a kickback scheme.
News 4 Jax reports that a Florida bill to prevent life and long-term care insurers from using genetic information in their coverage decisions has easily passed one committee.
In Science this week: potentially pathogenic mutations found in hematopoietic stem cells from young healthy donors, and more.